|
🐜
|
Brain cell type–specific enhancer–promoter interactome maps and disease-risk association
26 auth.
A. Nott,
I. Holtman,
N. Coufal,
J. Schlachetzki,
Miao Yu,
Rong Hu,
Claudia Z. Han,
Monique Pena,
Jiayang Xiao,
Yin Wu,
Zahara Keulen,
M. Pasillas,
Carolyn O’Connor,
C. Nickl,
Simon T. Schafer,
...
Zeyang Shen,
R. Rissman,
J. Brewer,
D. Gosselin,
D. Gonda,
M. Levy,
M. Rosenfeld,
G. McVicker,
F. Gage,
B. Ren,
C. Glass
|
9 |
2019 |
9
🐜
|
|
🐬
|
Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation.
W. Dostmann,
Mark S. Taylor,
C. Nickl,
J. Brayden,
Ronald Frank,
W. Tegge
|
7 |
2000 |
7
🐬
|
|
🐬
|
Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation.
M. Taylor,
Chris Okwuchukwuasanya,
C. Nickl,
W. Tegge,
J. Brayden,
W. Dostmann
|
5 |
2004 |
5
🐬
|
|
🐜
|
Delineation of selective cyclic GMP-dependent protein kinase Ialpha substrate and inhibitor peptides based on combinatorial peptide libraries on paper.
8 auth.
W. Dostmann,
W. Dostmann,
C. Nickl,
C. Nickl,
Stefan Thiel,
Igor F. Tsigelny,
...
Ronald Frank,
W. Tegge
|
5 |
1999 |
5
🐜
|
|
🐜
|
Delineation of selective cyclic GMP-dependent protein kinase Ialpha substrate and inhibitor peptides based on combinatorial peptide libraries on paper.
8 auth.
W. Dostmann,
W. Dostmann,
C. Nickl,
C. Nickl,
Stefan Thiel,
Igor F. Tsigelny,
...
Ronald Frank,
W. Tegge
|
5 |
1999 |
5
🐜
|
|
🐬
|
Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Ialpha.
W. Dostmann,
W. Tegge,
R. Frank,
C. Nickl,
M. Taylor,
J. Brayden
|
5 |
2002 |
5
🐬
|
|
🐜
|
MLL Rearrangements Impact Outcome in HOXA-deregulated T-lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
31 auth.
K. Matlawska-Wasowska,
Huining Kang,
M. Devidas,
J. Wen,
R. Harvey,
C. Nickl,
S. Ness,
Michael C. Rusch,
Yongjin Li,
M. Onozawa,
C. Martínez,
B. Wood,
B. Asselin,
I. Chen,
K. Roberts,
...
A. Baruchel,
J. Soulier,
H. Dombret,
Jinghui Zhang,
R. Larson,
E. Raetz,
W. Carroll,
N. Winick,
P. Aplan,
M. Loh,
C. Mullighan,
S. Hunger,
N. Heerema,
A. Carroll,
K. Dunsmore,
S. Winter
|
5 |
2016 |
5
🐜
|
|
🐜
|
Integration of ruxolitinib into dose‐intensified therapy targeted against a novel JAK2 F694L mutation in B‐precursor acute lymphoblastic leukemia
9 auth.
Jodi R. Mayfield,
David R. Czuchlewski,
J. M. Gale,
K. Matlawska-Wasowska,
M. Vasef,
C. Nickl,
...
G. Pickett,
S. Ness,
S. Winter
|
5 |
2017 |
5
🐜
|
|
🐜
|
Epigenetic silencing of SOCS5 potentiates JAK‐STAT signaling and progression of T‐cell acute lymphoblastic leukemia
12 auth.
Nitesh D. Sharma,
C. Nickl,
Huining Kang,
Wojciech Ornatowski,
Roger B Brown,
S. Ness,
...
M. Loh,
C. Mullighan,
S. Winter,
S. Hunger,
J. Cannon,
K. Matlawska-Wasowska
|
4 |
2019 |
4
🐜
|
